Login to Your Account

Emisphere Down 26% After Osteoarthritis Endpoints Miss

By Tom Wall

Monday, October 17, 2011
Shares in Emisphere Technologies Inc. dropped sharply following the Cedar Knolls, N.J.-based firm's announcement that it was informed by partner Novartis Pharma AG that the first interpretable results of a second Phase III study of oral calcitonin in patients with osteoarthritis of the knee missed co-primary and secondary endpoints.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription